# 1. Financial Performance ## A. Key Figures * **Total Income:** **₹11,189 Mn** consolidated (+15%) * EBITDA (ex-Noida): ₹2,804 Mn (+14%) · 25.2% margin (-100 bps) * EBITDA (inc. Noida): ₹2,607 Mn (+6%) · 23.3% margin * PAT: ₹1,584 Mn (+21%) · 14.2% margin (+80 bps) * **Operating Cash Flow / Capex:** **₹3,295 Mn** OCF · **₹4,252 Mn** capex (H1 FY26) ## B. Revenue Growth * **Solid Top-Line Momentum:** Revenue growth reflects strong underlying demand and successful scaling across the hospital network. ## C. Profit Margins * **Noida Ramp-Up as Expected:** Medanta Noida generated ₹9 Cr revenue in its first month, incurring a ₹7 Cr EBITDA loss, consistent with initial phase guidance. * **Core Business Resilience:** EBITDA from developing hospitals (ex-Noida) surged with **34% YoY growth** and **5% margins**, signaling strong operating leverage. * **Margin Compression in Mature Assets:** Excluding Noida, core EBITDA margins declined slightly to **22%**, pressured by operational investments and mix. ## D. Balance Sheet * **Robust Liquidity Position:** Company maintains a net cash surplus of **₹20 Cr** as of September 2025, providing flexibility for ongoing investments. ## E. Cash Flow * **Capital Allocation Discipline:** H1 operating cash flow comfortably covered capex, which was primarily directed toward the Noida expansion and equipment modernization. --- # 2. Hospital & Bed Capacity ## A. Key Figures * Guwahati Hospital: 400+ beds planned · 3.5-acre land acquired (~₹60 Cr) * **Mumbai (Oshiwara):** Capacity expanded from **500 to 750 beds** · **₹1,530 Cr** total project cost * **Noida Hospital:** **226 beds** operational at launch (Sep 2025) · **550-bed** facility total capacity ## B. Bed Additions * **Strategic Regional Expansion:** New 400+ bed super specialty hospital in Guwahati to capture underserved Northeast demand, fully company-controlled with no PPP structure. * **Capacity Upside in Key Metro:** Mumbai Oshiwara expansion to 750 beds advances following FSI approval, positioning it as a premier Western India healthcare hub. * **Noida Ramp-Up Underway:** Sixth hospital launched in September 2025 with strong initial footprint; bed count increased to **~300** post-launch, signaling rapid scaling. * **Operational Flexibility:** Guwahati site benefits from Advantage Assam 0 investment policy, free from government bed allocation constraints. ## C. Facility Launches * **Noida Inauguration Imminent:** Official launch of the sixth facility expected shortly after a successful soft opening, featuring **over 80 ICU beds**, **5 OTs**, and **3 cath labs**. ## D. Construction Progress * **Guwahati Project Mobilizing:** Land possession and Bhoomi Pujan complete; design phase underway for 400+ bed facility on National Highway 27. * **Delhi-Area Projects Advancing:** South Delhi construction digging started; Pitampura awaiting plan approval before site activation. * **Near-Term OR Capacity Boost:** **9–10 additional operation rooms** expected online in coming weeks, enhancing surgical throughput. --- # 3. Volume & Utilization ## A. Key Figures * **Inpatient Volumes:** **+26%** YoY (Lucknow, Patna, Noida) · **+13%** YoY group-wide * **Outpatient Volumes:** **+15%** YoY * **Occupied Bed Days:** **+8%** YoY (expanded capacity base) * **ARPOB:** **₹54,980** (including Noida) ## B. Inpatient Volumes * **Strong Regional Momentum:** Robust double-digit inpatient volume growth in **Lucknow and Patna**, with Lucknow exceeding **30% IP growth** despite minimal bed additions, signaling high operational efficiency. * **New Site Contribution:** Noida is now operational and contributing to network volumes, reinforcing Medanta’s scalable hub-and-spoke expansion model. * **Sustained Demand:** No evidence of clinical attrition or patient shift to competitors over the **past 3–4 quarters**, affirming brand resilience and service quality. * **Volume Scalability:** Growth increasingly driven by procedural diversity and utilization gains rather than bed expansion, enhancing capital efficiency. ## C. Bed Occupancy * **Healthy Utilization Trajectory:** Developing hospitals achieving **70% occupancy** and **₹55k ARPOB**, indicating strong ramp-up potential as empanelments and specialty mix mature. * **Integrated Campus Strategy:** Ranchi’s growth remains constrained by pending empanelments, but optimization across its dual-site setup is expected to drive future volume and revenue uplift. --- # 4. Revenue & Pricing Trends ## A. Key Figures * **ARPOB:** **₹65,570** blended (6% YoY) * **Patna ARPOB:** **₹48,000–50,000** (strong growth) * **CGHS Revenue Contribution:** **11%–12%** of total revenue * **Length of Stay:** **3–6 days** (among lowest in industry) ## B. ARPOB Performance * **Blended ARPOB Growth:** Healthy 6% YoY increase driven by **strong realizations and volume expansion**, despite mixed city-level dynamics. * **Divergent City Trends:** Patna shows **robust ARPOB momentum** from higher-complexity procedures, while Lucknow stabilizes due to strategic expansion into lower-ARPOB specialties. * **Structural Over Short-Term:** ARPOB viewed as an outcome metric; management prioritizes **realization rates and case mix** over standalone ARPOB, especially amid length of stay optimization. * **Geographic ARPOB Gradient:** Clear hierarchy in ARPOB by location—**Mumbai > Delhi > Gurugram/Noida**—with metro-non-metro differences shaping network expansion economics. ## C. Price Increases * **Selective & Specialty-Driven Pricing:** Recent increases focused on **ENT, Cardiology, and Cancer**, ranging **5%–10%** for specific procedures, with no broad-based hikes. * **Conservative Pricing Philosophy:** **No price increases in Patna since inception**, despite financial strength, reflecting a **patient-friendly, targeted approach**; similar restraint in Lucknow and Gurugram. * **CGHS Impact Pending:** CGHS revisions mark first in years, but **no quantified revenue uplift** available; broader public sector follow-on possible. * **Insurance Renewal Timing:** Revisions staggered due to **multi-year contracts**, limiting immediate pass-through of pricing changes. ## D. CGHS & ECHS Revenue * **Stable Government Segment:** CGHS and ECHS together represent **11%–12%** of revenue, with CGHS alone ~50% of that pool; recent rate hikes offer margin tailwinds, though magnitude remains unquantified. --- # 5. Segment & Geography Mix ## A. Key Figures * Revenue (Matured Hospitals): ₹7,200 Mn (Gurugram, Indore, Ranchi) (+5% YoY) · ₹3,570 Mn (Developing Hospitals, incl. Noida) (+30% YoY) * EBITDA (Matured Hospitals): ₹1,696 Mn (23.5% margin) (+2.2% adj. YoY) * **ARPOB (Matured Hospitals):** **₹73,447** (+10% YoY) * **International Patient Revenue:** **₹762 Mn** (Q2 FY26) (+49% YoY) ## B. Mature Hospitals * **Resilient Core Performance:** Mature facilities delivered solid underlying revenue growth and margin stability despite pharmacy business divestment and rising manpower costs. * **Volume and Pricing Momentum:** Inpatient admissions rose modestly with expanded capacity; **ARPOB growth of 10%** reflects favorable specialty mix and pricing power. * **Strategic Reinvestment:** Ongoing investments support long-term EBITDA alignment, with recent trends indicating accelerated performance in mature units over the past six months. ## C. Developing Hospitals * **High-Growth Trajectory:** Developing hospitals posted strong double-digit revenue growth, led by Lucknow and Patna, with significant bed capacity added in Noida and Patna. * **Path to Maturity:** Lucknow, approaching 6 years of operation, may be reclassified as mature next year, having achieved **~15% first-year EBITDA margin**, outperforming Patna’s **~8%**. ## D. International Patients * **Surge in Cross-Border Demand:** International patient revenue nearly doubled in Q2, driven by robust volume growth, signaling enhanced global brand appeal. * **Inclusive Access Model:** No restrictions on patient type or payer class, reinforcing Medanta’s commitment to broad-based, high-quality care delivery. --- # 6. Clinical & Talent Development ## A. Doctor Hiring * **Headline:** Noida unit has scaled clinical team with **150 doctors** onboarded, though hiring remains ongoing to match bed capacity expansion. * **Headline:** Senior leadership hiring is largely complete, with strong interest from top faculty reflecting confidence in Noida’s growth potential. * **Headline:** Key talent additions across **Paediatrics, Oncology, Surgery, Neurology, Neurosurgery, and Cardiology** have strengthened service delivery and performance. ## B. Specialty Expansion * **Headline:** Facility equipped with **cutting-edge technologies** including Da Vinci Xi robot, Artis Icono BiPlane CATH Lab, and 3 Tesla MRI, enabling advanced, precision-driven care. * **Headline:** Strategic expansion underway at Lucknow with plans for **1–2 new specialties** and a comprehensive rehabilitation center. * **Headline:** Oncology services currently absent at Ranchi campus but set for future rollout following specialty alignment with Noida. ## C. Talent Retention * **Headline:** Gurugram unit maintains **stable senior leadership** with no attrition at HOD or HOD-minus-1 levels over the past 4–6 quarters. * **Headline:** Medanta continues to be a preferred destination for clinicians, supported by strong retention in critical roles and successful recruitment momentum. --- # 7. Risks & Healthcare Factors ## A. Key Figures * **CGHS/ ECHS Realization Time:** **7–8 months** average (up to **9+ months**) due to new portal transition * **Overall Debtor Days:** **80 to 90 days** for credit business * **New Beds Added:** **110 beds** from expanded Ranchi facility ## B. Payment Delays * **Persistent Government Payment Delays:** CGHS and ECHS face **extended realization cycles** of 7–9+ months due to systemic delays and transition to a new portal, constraining cash flow parity with insurance or PSU business. * **Operational Drag from High Base Effect:** Unseasonably high vector-borne disease incidence in **Indore and Gurugram** created tough YoY comparisons, though performance recovery is expected in coming quarters. * **Faster PSU Collections:** PSU business benefits from **significantly shorter payment cycles**, contrasting sharply with CGHS/ECHS delays. ## C. New Facility Losses * **Ranchi Expansion Driving Near-Term Costs:** Integration of **110 new beds** and expanded specialties is increasing manpower and operating expenses, with EBITDA improvement expected as utilization stabilizes. * **No Standalone Loss Disclosure for Ranchi:** New and existing units operate as a **single integrated campus**, making isolated financial reporting impractical. * **Robotic Surgery Not a Cost Saver:** Despite operational advantages, robotic procedures add **significant consumable and instrumentation costs**, with surgeon and clinical expenses unchanged—only one component of rising cost pressures. * **Broader Cost Inflation Pressures:** Rising pharmaceutical use, **CAR-T cell therapy adoption**, and **antibiotic resistance** are key contributors to cost escalation beyond robotics. ## D. Talent Competition * **Intensifying Clinical Talent Wars:** Competition for **high-quality, ethical full-time clinicians** is escalating across all hospital types—listed, private, charitable, and government—particularly beyond NCR. * **Lucknow Market Stability:** Despite sector-wide expansion, competitive intensity in **Lucknow remains unchanged**, with growth attributed to internal operational improvements rather than reduced rivalry. --- # 8. Guidance & Outlook ## A. Key Figures * **Project Timeline:** **3 to 4 years** from construction to commissioning (based on Noida’s **3-year completion**) ## B. Noida Ramp-Up * **Elevated Costs Ahead:** Noida-related operational expenses to remain high in Q3 and Q4 FY26 as the facility continues ramping up. * **Faster Talent Deployment:** Majority of senior clinicians onboarded within first month—significantly quicker than Patna’s 6–12 month staggered hiring—boosting early momentum. * **Strong Market Positioning:** Benefits from Medanta’s established brand in Delhi NCR via 15-year-old Gurugram hospital, enabling faster patient and insurer acceptance versus new markets. * **Insurance Empanelments Imminent:** Progress expected within days to weeks; management anticipates most empanelments completed by year-end. ## C. Future Projects * **Capital Discipline:** All new hospitals expected to follow 3–4 year development cycle, with Noida serving as the benchmark timeline. ## D. Growth Strategy * **Sustained Investment Focus:** Growth driven by ongoing infrastructure and human capital investments, not one-off events, with further hiring planned. * **Breakeven Not Guided:** No timeline provided for Noida’s profitability—management prioritizes long-term capability building over short-term metrics. * **Proven Expansion Model:** Past success in overcoming skepticism in Lucknow and Patna validates clinical and financial viability of entering underserved markets. * **Localized Performance:** Each hospital assessed independently due to varying local dynamics; no direct comparisons to prior units.